Key Takeaways
- • Healthcare private equity fundraising is experiencing a mini-surge in 2024-2025, with established specialists closing funds above their target amounts, signaling revived dealmaking momentum in the sector.
- • Linden Capital Partners closed its sixth flagship healthcare fund at $5.4 billion, exemplifying the strength of fundraising activity within the healthcare PE space through Q3 2025.
- • Healthcare PE exit activity rebounded significantly in 2024 to an estimated $156 billion in value—the second-highest level on record—after a muted 2023, providing tailwinds for fresh fundraising.
- • Healthcare represented 7 percent of global buyout deal volume last year, demonstrating its persistent importance as a core investment thesis for institutional capital.
- • The sector's investment trajectory has accelerated substantially, with PE healthcare capital deployment growing from $5 billion in 2000 to $104 billion in 2024, reflecting sustained institutional appetite.
Summary
Healthcare private equity fundraising is showing signs of renewed momentum heading into late 2025, with multiple established sector specialists successfully closing funds above their stated targets. This apparent mini-surge reflects broader revitalization in healthcare dealmaking after a more subdued 2023-2024 period.
Linden Capital Partners exemplified this trend by closing its sixth flagship healthcare fund at $5.4 billion, demonstrating continued institutional investor confidence in dedicated healthcare platforms. The fundraising strength appears tied to improved exit conditions: healthcare PE exits reached an estimated $156 billion in 2024, representing the second-highest level ever recorded and a substantial recovery from the prior year's performance.
Healthcare maintains its position as a cornerstone sector within the broader private equity landscape, accounting for 7 percent of global buyout deal volume. This sustained allocation reflects the sector's structural appeal—recurring revenue streams, demographic tailwinds, and essential service characteristics have long attracted institutional capital. The growth trajectory has been pronounced: private equity healthcare investments expanded from $5 billion in 2000 to $104 billion in 2024, underscoring how the asset class has evolved into a major capital deployment channel.
The trajectory of this fundraising momentum—particularly the performance of emerging funds like Patient Square's Fund II—will serve as a key barometer for whether current activity constitutes a cyclical upturn or reflects more durable structural demand shifts. For institutional investors monitoring healthcare PE exposure, the combination of strong exits, robust fundraising, and elevated dealmaking activity suggests the sector remains actively positioned within LP allocation decisions.
Linden Capital Partners exemplified this trend by closing its sixth flagship healthcare fund at $5.4 billion, demonstrating continued institutional investor confidence in dedicated healthcare platforms. The fundraising strength appears tied to improved exit conditions: healthcare PE exits reached an estimated $156 billion in 2024, representing the second-highest level ever recorded and a substantial recovery from the prior year's performance.
Healthcare maintains its position as a cornerstone sector within the broader private equity landscape, accounting for 7 percent of global buyout deal volume. This sustained allocation reflects the sector's structural appeal—recurring revenue streams, demographic tailwinds, and essential service characteristics have long attracted institutional capital. The growth trajectory has been pronounced: private equity healthcare investments expanded from $5 billion in 2000 to $104 billion in 2024, underscoring how the asset class has evolved into a major capital deployment channel.
The trajectory of this fundraising momentum—particularly the performance of emerging funds like Patient Square's Fund II—will serve as a key barometer for whether current activity constitutes a cyclical upturn or reflects more durable structural demand shifts. For institutional investors monitoring healthcare PE exposure, the combination of strong exits, robust fundraising, and elevated dealmaking activity suggests the sector remains actively positioned within LP allocation decisions.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.